Lead Product(s) : Fexinidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fexinidazole Winthrop is reffered to as the first oral treatment of acute form of sleeping sickness (rhodesiense) which is found in East and Southern Africa.
Product Name : Fexinidazole Winthrop
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 15, 2023
Lead Product(s) : Fexinidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fexinidazole
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2022
Lead Product(s) : Fexinidazole
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fexinidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves Fexinidazole as The First All-Oral Treatment for Sleeping Sickness
Details : The US Food and Drug Administration has approved fexinidazole as the first alloral treatment for both stages of the Trypanosoma brucei gambiense form of sleeping sickness (Human African trypanosomiasis) in patients 6 years of age and older and weighing a...
Product Name : Fexinidazole Winthrop
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 19, 2021
Lead Product(s) : Fexinidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fexinidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Sanofi
Deal Size : $25.0 million
Deal Type : Collaboration
Sanofi Renews Deal with Who to Fight Tropical Diseases
Details : A new five-year US$ 25 million (US$ 5 million/year) financial support to prevent and treat Neglected Tropical Diseases. The development of the first oral drug, fexinidazole, in partnership with DNDi, has simplified the treatment of patients in the most r...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 15, 2020
Lead Product(s) : Fexinidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Sanofi
Deal Size : $25.0 million
Deal Type : Collaboration
Lead Product(s) : Fexinidazole
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 20, 2017
Lead Product(s) : Fexinidazole
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fexinidazole
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Fexinidazole (1200mg) Bioavailability Under Different Food Intake Conditions
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 22, 2011
Lead Product(s) : Fexinidazole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Sanofi
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
